-
公开(公告)号：US20080274969A1
公开(公告)日：2008-11-06
申请号：US12114477
申请日：2008-05-02
申请人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott M. Kee , Darrell Sleep , Robert Charles Ladner , Arthur C. Ley
发明人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott M. Kee , Darrell Sleep , Robert Charles Ladner , Arthur C. Ley
CPC分类号： C12N15/62 , C07K2319/31
摘要： The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.
摘要翻译： 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质，例如与白蛋白或其片段或变体融合的Kunitz结构域肽（包括但不限于其片段和变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白，用这些核酸和载体转化的宿主细胞的核酸分子和载体，以及使用这些核酸，载体和/或宿主制备本发明的白蛋白融合蛋白的方法 细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶，激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。
-
公开(公告)号：US20110092413A1
公开(公告)日：2011-04-21
申请号：US12917903
申请日：2010-11-02
申请人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott M. Kee , Darrell Sleep , Robert Charles Ladner , Arthur C. Ley
发明人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott M. Kee , Darrell Sleep , Robert Charles Ladner , Arthur C. Ley
CPC分类号： C12N15/62 , C07K2319/31
摘要： The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules and vectors encoding the albumin fusion proteins of the invention, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.
摘要翻译： 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质，例如与白蛋白或其片段或变体融合的Kunitz结构域肽（包括但不限于其片段和变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白，用这些核酸和载体转化的宿主细胞的核酸分子和载体，以及使用这些核酸，载体和/或宿主制备本发明的白蛋白融合蛋白的方法 细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶，激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。
-
公开(公告)号：US20050222023A1
公开(公告)日：2005-10-06
申请号：US10503834
申请日：2003-02-07
申请人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott Kee , Darrell Sleep , Robert Ladner , Arthur Ley
发明人： Hans-Peter Hauser , Thomas Weimer , Val Romberg , Scott Kee , Darrell Sleep , Robert Ladner , Arthur Ley
IPC分类号： C07K14/675 , C12N15/62
CPC分类号： C12N15/62 , C07K2319/31
摘要： The invention relates to proteins comprising serine protease inhibiting peptides, such as Kunitz domain peptides (including, but not limited to, fragments and variants thereof) fused to albumin, or fragments or variants thereof. These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses, therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting neutrophil elastase, kallikrein, and plasmin. The invention further relates to compositions and methods for treating cystic fibrosis and cancer.
摘要翻译： 本发明涉及包含丝氨酸蛋白酶抑制肽的蛋白质，例如与白蛋白或其片段或变体融合的Kunitz结构域肽（包括但不限于其片段和变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制嗜中性粒细胞弹性蛋白酶，激肽释放酶和纤溶酶的组合物和方法。 本发明还涉及治疗囊性纤维化和癌症的组合物和方法。
-
公开(公告)号：US20100143973A1
公开(公告)日：2010-06-10
申请号：US12626107
申请日：2009-11-25
IPC分类号： C07K19/00 , C12P21/00 , C12N5/10 , C12N1/21 , C12N1/15 , C12N1/19 , C12N15/63 , C07H21/04 , C07K14/54
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译： 本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
-
公开(公告)号：US20080293638A1
公开(公告)日：2008-11-27
申请号：US12167537
申请日：2008-07-03
申请人： Mathias Jurs , Thomas Weimer , Hans-Peter Hauser , Darrell Sleep
发明人： Mathias Jurs , Thomas Weimer , Hans-Peter Hauser , Darrell Sleep
CPC分类号： C07K14/475 , A61K38/00 , C07K14/765 , C07K2319/31
摘要： The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof.
摘要翻译： 本发明涉及包含白蛋白或其片段或变体或衍生物和活化睫状神经营养因子（CNTF）受体的至少一种生物活性肽或其片段或变体或衍生物的融合蛋白。
-
公开(公告)号：US20120258072A1
公开(公告)日：2012-10-11
申请号：US13278757
申请日：2011-10-21
IPC分类号： C07K19/00 , A61P7/02 , A61P1/00 , C12N5/10 , C12P21/02 , C12N15/63 , C12N1/19 , A61K38/20 , C12N15/62
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or anti-inflammatory properties, fused to albumin (including, but not limited to, fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译： 本发明涉及包含白细胞介素11（IL-11）（包括但不限于其片段和变体）的蛋白质，其表现出与白蛋白融合的血小板生成或抗炎特性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子，以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法， 载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
-
公开(公告)号：US20080292581A1
公开(公告)日：2008-11-27
申请号：US10584438
申请日：2004-12-03
IPC分类号： C07K14/54 , C12N15/24 , C12N15/81 , C12N15/85 , C12P21/02 , C12N5/10 , C12N1/19 , A61P1/00 , A61P3/00 , A61K38/20
CPC分类号： A61K38/38 , A61K38/2073 , C07K14/5431 , C07K14/76 , C07K14/765 , C07K2319/31 , Y02A50/473
摘要： The invention relates to proteins comprising Interleukin 11 (IL-11) (including, but not limited to, fragments and variants thereof), which exhibit thrombopoietic or antiinflammatory properties, fused to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention”. These fusion proteins exhibit extended shelf-life and/or pharmacokinetic properties and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for treatment or prophylaxis of thrombocytopenia or inflammatory diseases.
摘要翻译： 本发明涉及与白蛋白（包括但不限于白蛋白的片段或变体）融合的表现出血小板生成或抗炎特性的白介素11（IL-11）（包括但不限于其片段和变体）的蛋白质， 。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或药代动力学性质和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及用于治疗或预防血小板减少症或炎性疾病的组合物和方法。
-
公开(公告)号：US20060241027A1
公开(公告)日：2006-10-26
申请号：US10503832
申请日：2003-02-07
申请人： Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
发明人： Hans-Peter Hauser , Thomas Weimer , Darrell Sleep
IPC分类号： C07K14/765 , C07K14/16 , A61K39/12
CPC分类号： C07K14/005 , C07K14/76 , C07K2319/31 , C12N2740/16122
摘要： The invention relates to proteins comprising HIV fusion inhibiting peptides, such as T-20 and/or T-1249 peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused to albumin (including, but nbot limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as “albumin fusion proteins of the invention.” These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting HIV-induced cell fusion. The invention further relates to compositions and methods for inhibiting HIV transmission to uninfected cells.
摘要翻译： 本发明涉及包含HIV融合抑制肽的蛋白质，例如T-20和/或T-1249肽（包括但不限于其片段和变体），其表现出与白蛋白融合的抗逆转录病毒活性（包括， 但限于白蛋白的片段或变体）。 这些融合蛋白在本文中统称为“本发明的白蛋白融合蛋白”。 这些融合蛋白具有延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及用于抑制HIV诱导的细胞融合的组合物和方法。 本发明还涉及用于抑制HIV向未感染细胞传播的组合物和方法。
-
公开(公告)号：US20060178301A1
公开(公告)日：2006-08-10
申请号：US11051615
申请日：2005-02-04
申请人： Mathias Jurs , Thomas Weimer , Hans-Peter Hauser , Darrell Sleep
发明人： Mathias Jurs , Thomas Weimer , Hans-Peter Hauser , Darrell Sleep
IPC分类号： A61K38/18 , C07K14/475 , C07K14/52
CPC分类号： C07K14/475 , A61K38/00 , C07K14/765 , C07K2319/31
摘要： The invention relates to a fusion protein comprising an albumin, or a fragment or a variant or a derivative thereof and at least one biologically active peptide which activates the ciliary neurotrophic factor (CNTF) receptor, or a fragment or variant or a derivative thereof.
摘要翻译： 本发明涉及包含白蛋白或其片段或变体或衍生物和活化睫状神经营养因子（CNTF）受体的至少一种生物活性肽或其片段或变体或衍生物的融合蛋白。
-
公开(公告)号：US20120263747A1
公开(公告)日：2012-10-18
申请号：US13285727
申请日：2011-10-31
申请人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
发明人： Peter Mertins , Ilhan Celik , Oliver Kisker , Darrell Sleep , Joanna Hay , Hans-Peter Hauser
IPC分类号： C07K19/00 , A61P9/10 , A61P9/00 , A61K39/385 , A61K48/00 , A61P37/04 , A61P29/00 , A61P19/02 , A61P17/06 , A61P27/02 , A61P1/00 , A61P17/00 , A61P17/02 , A61P1/04 , A61K38/38
CPC分类号： A61K38/39 , A01K2217/05 , A61K9/0019 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K39/0005 , A61K47/643 , A61K48/00 , A61K2039/53 , C07K14/005 , C07K14/47 , C07K14/765 , C07K14/78 , C07K14/8114 , C07K2319/00 , C07K2319/31 , C12N15/62 , C12N2740/16122 , C12Y301/26003
摘要： The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis.
摘要翻译： 本发明涉及包含血管生成抑制肽（例如内皮抑素肽（包括但不限于其片段和变体））的蛋白质，其表现出与白蛋白融合或缀合的抗逆转录病毒活性（包括但不限于片段或变体 的白蛋白）。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在本文中统称为白蛋白融合蛋白。 这些融合蛋白在溶液中表现出延长的保质期和/或延长或治疗活性。 本发明包括治疗性白蛋白融合蛋白，组合物，药物组合物，制剂和试剂盒。 本发明还包括编码本发明的白蛋白融合蛋白的核酸分子以及含有这些核酸的载体，用这些核酸和载体转化的宿主细胞，以及使用这些核酸制备本发明的白蛋白融合蛋白的方法 ，载体和/或宿主细胞。 本发明还涉及抑制血管内皮细胞增殖和肿瘤发生生成诱导的细胞融合的组合物和方法。 本发明还涉及预防原发性肿瘤和转移瘤的生长或促进消退的组合物和方法; 并用于治疗癌症，糖尿病性视网膜病变，进行性黄斑变性或类风湿性关节炎。
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.045 秒)
